Biblio
Journal Article
Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.
von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink A-M, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, et al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia. 2022.